JP2020513243A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513243A5
JP2020513243A5 JP2019529896A JP2019529896A JP2020513243A5 JP 2020513243 A5 JP2020513243 A5 JP 2020513243A5 JP 2019529896 A JP2019529896 A JP 2019529896A JP 2019529896 A JP2019529896 A JP 2019529896A JP 2020513243 A5 JP2020513243 A5 JP 2020513243A5
Authority
JP
Japan
Prior art keywords
cells
composition
cell
immune cells
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019529896A
Other languages
English (en)
Japanese (ja)
Other versions
JP7098615B2 (ja
JP2020513243A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064507 external-priority patent/WO2018106595A1/en
Publication of JP2020513243A publication Critical patent/JP2020513243A/ja
Publication of JP2020513243A5 publication Critical patent/JP2020513243A5/ja
Priority to JP2022104666A priority Critical patent/JP2022130607A/ja
Application granted granted Critical
Publication of JP7098615B2 publication Critical patent/JP7098615B2/ja
Priority to JP2023172588A priority patent/JP7885190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019529896A 2016-12-05 2017-12-04 養子免疫療法における免疫細胞調節のための組成物および方法 Active JP7098615B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022104666A JP2022130607A (ja) 2016-12-05 2022-06-29 養子免疫療法における免疫細胞調節のための組成物および方法
JP2023172588A JP7885190B2 (ja) 2016-12-05 2023-10-04 養子免疫療法における免疫細胞調節のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662430263P 2016-12-05 2016-12-05
US62/430,263 2016-12-05
PCT/US2017/064507 WO2018106595A1 (en) 2016-12-05 2017-12-04 Compositions and methods for immune cell modulation in adoptive immunotherapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022104666A Division JP2022130607A (ja) 2016-12-05 2022-06-29 養子免疫療法における免疫細胞調節のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020513243A JP2020513243A (ja) 2020-05-14
JP2020513243A5 true JP2020513243A5 (cg-RX-API-DMAC10.html) 2020-08-13
JP7098615B2 JP7098615B2 (ja) 2022-07-11

Family

ID=62491299

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019529896A Active JP7098615B2 (ja) 2016-12-05 2017-12-04 養子免疫療法における免疫細胞調節のための組成物および方法
JP2022104666A Pending JP2022130607A (ja) 2016-12-05 2022-06-29 養子免疫療法における免疫細胞調節のための組成物および方法
JP2023172588A Active JP7885190B2 (ja) 2016-12-05 2023-10-04 養子免疫療法における免疫細胞調節のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022104666A Pending JP2022130607A (ja) 2016-12-05 2022-06-29 養子免疫療法における免疫細胞調節のための組成物および方法
JP2023172588A Active JP7885190B2 (ja) 2016-12-05 2023-10-04 養子免疫療法における免疫細胞調節のための組成物および方法

Country Status (4)

Country Link
US (2) US11932870B2 (cg-RX-API-DMAC10.html)
EP (1) EP3548049A4 (cg-RX-API-DMAC10.html)
JP (3) JP7098615B2 (cg-RX-API-DMAC10.html)
WO (1) WO2018106595A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3600357A4 (en) * 2017-03-31 2021-01-06 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING
US12036241B2 (en) 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CA3082575A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US20200040056A1 (en) * 2018-05-31 2020-02-06 Washington University Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
EP3835416A4 (en) * 2018-08-10 2022-06-08 Eutilex Co., Ltd. METHOD FOR THE PREPARATION AND CRYOPRESERVATION OF CD8+ T CELLS SPECIFIC FOR A CANCER ANTIGEN
CN112888786A (zh) * 2018-09-07 2021-06-01 Sotio有限责任公司 与调节细胞内乳酸浓度的反式代谢分子组合的嵌合受体多肽及其治疗用途
CA3114385A1 (en) * 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
AU2019377461A1 (en) * 2018-11-06 2021-05-27 Washington University Chimeric antigen receptor memory-like (CARML) NK cells and methods of making and using same
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
CN110157680A (zh) * 2019-05-08 2019-08-23 浙江大学 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法
CN112300997A (zh) * 2019-08-01 2021-02-02 上海赛比曼生物科技有限公司 通用型car-t细胞及其制备和应用
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
JP2022554217A (ja) * 2019-10-23 2022-12-28 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 養子免疫療法
KR102300846B1 (ko) * 2019-11-01 2021-09-09 서울대학교산학협력단 면역 활성 개선용 조성물 및 이의 방법
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
AU2022209191A1 (en) * 2021-01-12 2023-07-06 The Scripps Research Institute Small molecules for reprograming anti-tumor immunity of t cells
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4071248A1 (en) 2021-04-07 2022-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Means and methods for enhancing receptor-targeted gene transfer
EP4519418A1 (en) * 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
EP4636093A1 (en) * 2024-04-19 2025-10-22 Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel Targeting mapk-erk pathway for enhancing nucleic acid delivery
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003455C (en) 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
HK1048302A1 (zh) 1999-08-13 2003-03-28 大正制药株式会社 前列腺素衍生物
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20040175373A1 (en) 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Mek雜環抑制劑及其使用方法
WO2007103901A2 (en) 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
GB2444853B (en) 2006-12-14 2010-02-24 Medical Res Council Methods & uses
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
AU2009322346B2 (en) 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
EP2375897A4 (en) 2009-01-14 2013-05-15 Health Research Inc METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
RS61406B1 (sr) 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
EP3191126B1 (en) * 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CA2980592A1 (en) * 2015-03-27 2016-10-06 Nantkwest, Inc. Nk-92 cells in combination therapy with cancer drugs
HK1247958A1 (zh) 2015-05-05 2018-10-05 菲特治疗公司 T淋巴细胞的调节
CN107849102B (zh) * 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
WO2017040324A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3638775A1 (en) * 2017-06-13 2020-04-22 Fate Therapeutics, Inc. Compositions and methods for inducing myeloid suppressive cells and use thereof

Similar Documents

Publication Publication Date Title
US20250215396A1 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
US20240263135A1 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
US12419870B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
CN109415699B (zh) Cd4cd8双阳性t细胞的制备方法
JP2024123210A (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
JP2022078215A (ja) 多能性幹細胞からhlaホモ接合免疫細胞への指向分化方法
JP7668781B2 (ja) 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法
JP7747352B2 (ja) 操作されたガンマデルタt細胞ならびにその作製方法および使用方法
AU2016344779A1 (en) Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells
CN119256076A (zh) 用于产生调节性t细胞的方法
WO2022059780A1 (ja) iPS細胞を介する再生T細胞の製造方法
HK40092133A (en) Compositions and methods for immune cell modulation in adoptive immunotherapies